Form 4: Arcus Biosciences COO Receives Equity Grants

Jennifer Jarrett, Chief Operating Officer of Arcus Biosciences, Inc., was granted 31,000 restricted stock units and 126,000 stock options.

Summary

• Jennifer Jarrett, Chief Operating Officer of Arcus Biosciences, Inc. (RCUS), received equity grants on January 23, 2026.
• The grants include 31,000 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• These RSUs will vest in four equal annual installments, commencing on December 15, 2026, contingent on continued service.
• Additionally, 126,000 stock options were granted with an exercise price of $22.13 per share.
• The stock options become exercisable in 48 equal monthly installments starting after January 1, 2026, also subject to continued service.
• The options have an expiration date of January 22, 2036.
• Following these transactions, Jennifer Jarrett beneficially owns 224,024 shares of Common Stock, which includes the unvested portion of her RSU grants, and 126,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: This is a routine disclosure of executive compensation via equity grants, which is a neutral event in itself. It reflects standard corporate governance practices for incentivizing management.

Positives

• The equity grants align the Chief Operating Officer's interests with those of shareholders, incentivizing long-term performance.
• The vesting schedules for both RSUs and stock options promote executive retention over several years.

Negatives

• No specific negative aspects are disclosed in this routine insider transaction filing.

Risks

• No specific risks are mentioned in this Form 4 filing, which is a disclosure of an insider transaction.

Future Outlook

The grants of restricted stock units and stock options, with their multi-year vesting schedules, indicate an expectation of continued service from the Chief Operating Officer and a long-term incentive structure tied to the company's future performance.

Management Comments

• No direct management comments or quotes are typically included in a Form 4 filing, which is a transactional disclosure.

Industry Context

The granting of equity awards such as restricted stock units and stock options is a standard practice in the biotechnology and pharmaceutical industries for executive compensation. This approach is widely used to attract, retain, and motivate key personnel by linking their financial incentives to the company's stock performance and long-term success.

Comparison to Industry Standards

• Executive compensation packages in the biotech sector frequently include a significant equity component, similar to the RSU and stock option grants observed here.
• Vesting schedules, such as the four-year annual vesting for RSUs and 48-month monthly vesting for options, are common mechanisms to ensure executive retention and align interests with long-term shareholder value, consistent with practices at comparable companies in the biopharmaceutical space.
• The specific size of the grant would typically be benchmarked against peer companies of similar market capitalization and stage of development, though this filing does not provide such comparative data.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings are mentioned in this Form 4 filing.

Related Party Transactions

• The equity grants to the Chief Operating Officer are a form of compensation and are considered an insider transaction, but not a related party transaction in the sense of a special, non-arm's length deal outside of standard compensation.

Stakeholder Impact

• Shareholders: The grants aim to align management's interests with shareholders by tying compensation to stock performance and long-term value creation. Dilution from future share issuance upon vesting/exercise is a consideration.
• Employees: May signal stability in executive leadership and a commitment to long-term incentives.

Next Steps

• Jennifer Jarrett's continued service to Arcus Biosciences, Inc. to fulfill vesting conditions for both RSUs and stock options.
• Future disclosures will be made as RSUs vest or options are exercised/expire.

Key Dates

Keywords

Arcus Biosciences, RCUS, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Executive Compensation, Jennifer Jarrett, Chief Operating Officer